Navigation Links
Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parkinson's Disease
Date:10/25/2012

SUNNYVALE, Calif., Oct. 25, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not. 

In Parkinson's disease, the nigro-striatal network (substantia nigra – striatum) is compromised due to the degeneration of dopaminergic neurons in the substantia nigra, which results in dopaminergic nerve terminal retraction from the striatum towards the substantia nigra. This leaves the striatum with inadequate dopamine levels, which in turn causes motor function deficits and other symptoms. Currently approved drugs that relieve symptoms focus on replacing the dopamine lost in the striatum; however, the symptom relief is temporary and the drugs typically lose their ability to abate symptoms roughly 7-10 years after the initiation of drug therapy. There are no approved therapies that focus on re-innervating the striatum by protecting dopaminergic neuron cell bodies in the substantia nigra while restoring dopaminergic innervation in the striatum.

In rat studies conducted by an independent academic laboratory contracted by Amarantus, 6-OHDA was injected directly into the striatum on one side of each rat's brain, causing their dopaminergic terminals to retract from the striatum towards the substantia
'/>"/>

SOURCE Amarantus BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Jan. 23, 2015  The Partnership to Fight Chronic Disease (PFCD) released ... care leaders and a new study analyzing the impact of increased ... a nationwide coalition working to educate policy makers and the public ... Capitol was focused on how the Iowa ...
(Date:1/23/2015)... Fla. and DUBLIN , Jan. ... the agreement with KRS Global Biotechnology, Inc. for the compounding, ... be compounded for shipment in the United States ... FDA approved Outsourcing Facility capable of compounding naltrexone tablets in ...
(Date:1/23/2015)... , Jan. 23, 2015  iMD Companies, Inc. (ICBU) has ... increase market share and grab a foothold in the hydroponic, ... production capabilities and a presence in the sector, and recently ... the growth of hemp and medical marijuana, iMD is committing ...
Breaking Medicine Technology:New research shows Iowa health exchange would benefit from improvements 2New research shows Iowa health exchange would benefit from improvements 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 2Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 3Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc. 4iMD Companies Poised to Make Impact in Multi-Billion Dollar Medical Marijuana Sector With Recent Investments and Strategic Partnerships 2
... , WILMINGTON, Del., Dec. 8 AstraZeneca (NYSE: ... Medicare Part D prescription savings program will no longer pay ... http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO ) , Prescriptions also now will ... changes to the AZ&Me(TM) Prescription Savings program for people with ...
... , PITTSBURGH, Dec. 8 Mylan Inc. (Nasdaq: ... has entered into settlement and license agreements with Wyeth, now ... (ER) Capsules, 37.5 mg, 75 mg and 150 mg, the ... major depressive disorder. , Pursuant to the license agreement, Mylan ...
Cached Medicine Technology:AstraZeneca Medicare Part D Patient Assistance Program No Longer Requires Co-Pays 2Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R) 2
(Date:1/22/2015)... a seasoned and trusted leader who consistently delivers trendy dresses ... it lead the wedding dress industry into the future. Today, ... the global market. , “The CEO of VogueQueen is uniquely ... continuing the goal of operational excellence and giving back to ...
(Date:1/22/2015)... 23, 2015 Angelweddingdress is a famous wedding ... its customers to follow it on Facebook, Twitter, and Pinterest. ... Day gift. Angelweddingdress draws a lottery every week. , Moreover, ... Feb. 28, 2015. Click Angelweddingdress homepage for more ...
(Date:1/22/2015)... AngelWeddingDress, the premier women’s dress supplier, has ... View website of AngelWeddingDress.com to find more ... dresses online for a bridal party. AngelWeddingDress offers a ... them. Its maternity wedding dresses are specially designed for ...
(Date:1/22/2015)... Juvent Sports ( http://www.juventsports.com ) and ... Merchandise Show to bestow a Juvent Sports Achievement award ... Arlene McKitrick. The award commemorated and congratulated McKitrick for ... She won her first amateur tournament in 1979 and ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
Breaking Medicine News(10 mins):Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4
... MAY 28 Family Health International announced today that ... from the Bill & Melinda Gates Foundation. The ... led by David C. Sokal, M.D., studying a novel ... Sokal,s project is one of 81 grants announced by ...
... Identify Developmental Delays and Promote GrowthNEW ORLEANS, May 28 ... - 11:30am , at 1315 Jefferson Highway , ... "Reach Out and Read " with Louisiana,s First Lady ... program. In this initiative, pediatricians encourage parents to read ...
... with a terminal illness, African-American seniors were two times ... life-prolonging treatments, according to a University of Pittsburgh study ... the Journal of General Internal Medicine . ... M.P.H., associate professor of medical, clinical and translational science ...
... owned subsidiary of sanofi-aventis U.S. LLC, has agreed to pay ... violated the False Claims Act by misreporting drug prices in ... Department announced today. ... that between 1995 and 2000, Aventis and its corporate predecessors ...
... Public/Private Partnership Launches at State Legislative Hearing TRENTON, N.J., ... that could cause grave harm to patient care in ... New Jersey Chamber of Commerce Foundation today announced a ... will have the nursing workforce it needs to meet ...
... Kyowa Hakko U.S.A., Inc. (Kyowa Hakko USA), the wholly ... has announced it has completed GRAS (Generally Recognized As ... Citicoline. Cognizin(R) is a branded form of Citicoline, a ... Citicoline provides an essential nutrient for cells -- ...
Cached Medicine News:Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 2Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 3Health News:Family Health International Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research Project Led by David Sokal, M.D. 4Health News:Ochsner Introduces Literacy Program to Promote Healthy Minds 2Health News:Blacks more likely to opt for life-sustaining measures at end of life 2Health News:Aventis Pharmaceutical to Pay U.S. $95.5 Million to Settle False Claims Act Allegations 2Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 2Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 3Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 4Health News:$22 Million Initiative Aims to Reverse New Jersey's Nurse Faculty Shortage, Avert Health Care Crisis 5Health News:Kyowa Hakko USA Announces GRAS Self-Affirmation for Novel Brain Health Ingredient Cognizin(R) Citicoline 2
Intended for the quantitative determination of glucose in serum. Reaction: endpoint. Wavelength: 500 nm. Linearity: 500 mg/dL (27.8 mmol/L)....
Inorganic phosphorus reagent is used for the quantitative determination of inorganic phosphorus in human serum....
For the quantitative kinetic determination of amylase activity, using manual or automated procedures, in human serum and urine....
Intended for the quantitative determination of gammaglutamyl transferase activity in serum or plasma. Single vial, dry powder reagent. Readily soluble at room temperature. Reaction: Kinetic. Waveleng...
Medicine Products: